Wells Fargo Gives a Hold Rating to Zimmer Biomet Holdings (ZBH)
In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Hold rating to Zimmer Biomet Holdings, with a price target of $90.00. The company’s shares closed yesterday at $82.94.
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Biegelsen covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Boston Scientific, and Medtronic. According to TipRanks, Biegelsen has an average return of 0.3% and a 47.00% success rate on recommended stocks.
Currently, the analyst consensus on Zimmer Biomet Holdings is a Hold with an average price target of $96.92, representing a 16.86% upside. In a report released on May 29, Citi also maintained a Hold rating on the stock with a $93.00 price target.
Based on Zimmer Biomet Holdings’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.09 billion and a net profit of $238.1 million. In comparison, last year the company earned a revenue of $1.91 billion and had a net profit of $182 million
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZBH in relation to earlier this year. Most recently, in March 2026, Lori Winkler, the SVP and CHRO of ZBH sold 2,650.00 shares for a total of $250,849.00.
Read More on ZBH:
Disclaimer & DisclosureReport an Issue
- Zimmer Biomet price target lowered to $93 from $95 at Citi
- Zimmer Biomet Shareholders Reaffirm Board, Leadership and Oversight
- Zimmer Biomet Completes Key Post‑Market Study on ZNN Bactiguard Nails
- Zimmer Biomet Expands 2026 Share Repurchase Program
- Zimmer Biomet increases share repurchase program by $250M
